Health Care Provider Use of Plasmodium Vivax Radical Cure (RC) With Tafenoquine or Primaquine After Semi-quantitative G6PD Testing: A Feasibility Study in Peru
The goal of this study is to evaluate the operational feasibility of using a new treatment algorithm for Malaria Vivax in Peru. The implementation package includes the following interventions: * A revised vivax treatment algorithm that incorporates new Radical Cure tools (G6PD test + Tafenoquine or Primaquine) * The training of Health Care Providers ( HCPs) in the revised algorithm and the use of the new RC tools * Patient counselling * A follow-up visit at Day 3 \[+2 days\] for patients after treatment start * Accompanying supporting measures: job aids, strengthening of supervision and PV processes
⁃ • All HCPs working in the selected facilities who are involved in the management of vivax patients.
• All patients aged 6 months onward, who have a confirmed P. vivax infection and who are treated in a study Health Facilities
• Pregnant and lactating women, who have a contra-indication to both Primaquine and Tafenoquine, but for whom correct case management will be evaluated as part of the primary endpoints.
• Patients providing informed consent and/or informed assent